Ionis Pharmaceuticals Inc
XMUN:ISI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Ionis Pharmaceuticals Inc
XMUN:ISI
|
US |
|
Indonesia Fibreboard Industry Tbk
IDX:IFII
|
ID |
|
S
|
Sumitomo Corp
F:SUMA
|
JP |
Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals is a drug company that makes medicines based on antisense technology, a way to turn off harmful proteins by targeting RNA before they are made. It spends most of its effort on discovering and developing treatments for serious diseases, especially rare genetic, neurological, cardiovascular, and metabolic conditions. Its pipeline is the main business asset: it creates drug candidates and then tests them through clinical development. Ionis usually makes money in two ways. It earns partnership income when larger pharmaceutical companies help fund development or commercialize a medicine, and it can also collect royalties, milestones, and, for some products, sales revenue. That means it is not a broad drug seller with many large in-house brands; it is more of a specialist research company that turns RNA science into medicines and often shares the later stages of development and marketing with partners. What makes Ionis different is its focus on antisense drugs, which can be designed to hit very specific disease targets. This gives it a clear role in the biotech value chain: it invents and advances the science, while partners often help with large-scale clinical trials, manufacturing, and sales. For investors, the business is easiest to think of as a research-driven platform company that aims to convert a steady stream of new drug ideas into licensing deals and marketed therapies.
Ionis Pharmaceuticals is a drug company that makes medicines based on antisense technology, a way to turn off harmful proteins by targeting RNA before they are made. It spends most of its effort on discovering and developing treatments for serious diseases, especially rare genetic, neurological, cardiovascular, and metabolic conditions. Its pipeline is the main business asset: it creates drug candidates and then tests them through clinical development.
Ionis usually makes money in two ways. It earns partnership income when larger pharmaceutical companies help fund development or commercialize a medicine, and it can also collect royalties, milestones, and, for some products, sales revenue. That means it is not a broad drug seller with many large in-house brands; it is more of a specialist research company that turns RNA science into medicines and often shares the later stages of development and marketing with partners.
What makes Ionis different is its focus on antisense drugs, which can be designed to hit very specific disease targets. This gives it a clear role in the biotech value chain: it invents and advances the science, while partners often help with large-scale clinical trials, manufacturing, and sales. For investors, the business is easiest to think of as a research-driven platform company that aims to convert a steady stream of new drug ideas into licensing deals and marketed therapies.
Strong Q1: Ionis reported first-quarter revenue of $246 million, up 87% year over year, helped by stronger commercial sales and about $95 million of milestone payments from partnerships.
Guidance raised: The company lifted 2026 total revenue guidance by $75 million to $875 million-$900 million and improved non-GAAP operating loss guidance to $425 million-$475 million.
TRYNGOLZA momentum: Management said demand for TRYNGOLZA was the strongest quarter to date and raised its U.S. peak sales estimate for TRYNGOLZA across FCS and sHTG to greater than $3 billion from greater than $2 billion.
Launch pipeline: Ionis said it is on track for three independent medicines on the market in 2026, with Olezarsen in sHTG expected by the June 30 PDUFA date and Zilganersen in Alexander’s disease by the September 22 PDUFA date.
DAWNZERA progress: DAWNZERA’s launch is gaining traction in a switch-heavy HAE market, and management now expects 2026 product sales of $110 million-$120 million.
Balance sheet: Cash ended the quarter at about $1.9 billion, and management said year-end 2026 cash should be greater than $1.6 billion after repaying convertible notes.
